TRANSPLANTATION PROCEEDINGS, vol.49, no.3, pp.541-545, 2017 (SCI-Expanded)
Background. The serum levels of galactose-deficient immunoglobulin (Ig)A1 (Gd-IgAl) represent the most promising candidate biomarker for IgA nephropathy (IgAN). The aim of this study was to evaluate the serum levels of Gd-IgAl as a novel noninvasive biomarker for post-transplant IgAN recurrence.